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Abstract
Background:  The combination of transfusion and chelation therapy has dramatically extended the life
expectancy of thalassemic patients. The main objective of this study is to determine the prevalence of prominent
thalassemia complications.
Methods:  Two hundred twenty patients entered the study. Physicians collected demographic and
anthropometric data and the history of therapies as well as menstrual histories. Patients have been examined to
determine their pubertal status. Serum levels of 25(OH) D, calcium, phosphate, iPTH were measured. Thyroid
function was assessed by T3, T4 and TSH. Zinc and copper in serum were determined by flame atomic absorption
spectrophotometry. Bone mineral density (BMD) measurements at lumbar and femoral regions have been done
using dual x-ray absorptiometry. The dietary calcium, zinc and copper intakes were estimated by food-frequency
questionnaires.
Results: Short stature was seen in 39.3% of our patients. Hypogonadism was seen in 22.9% of boys and 12.2% of
girls. Hypoparathyroidism and primary hypothyroidism was present in 7.6% and 7.7% of the patients. About 13 %
of patients had more than one endocrine complication with mean serum ferritin of 1678 ± 955 micrograms/lit.
Prevalence of lumbar osteoporosis and osteopenia were 50.7% and 39.4%. Femoral osteoporosis and osteopenia
were present in 10.8% and 36.9% of the patients. Lumbar BMD abnormalities were associated with duration of
chelation therapy. Low serum zinc and copper was observed in 79.6% and 68% of the study population
respectively. Serum zinc showed significant association with lumbar but not femoral BMD. In 37.2% of patients
serum levels of 25(OH) D below 23 nmol/l were detected.
Conclusion: High prevalence of complications among our thalassemics signifies the importance of more detailed
studies along with therapeutic interventions.
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Background
Beta-thalassemia represents a group of recessively inher-
ited hemoglobin disorders first described by Cooley and
Lee [1] and characterized by reduced synthesis of β -globin
chain. The homozygous state results in severe anemia,
which needs regular blood transfusion. The combination
of transfusion and chelation therapy has dramatically
extended the life expectancy of thalassemic patients who
can now survive into their fourth and fifth decades of life
[2,3] On the other hand, frequent blood transfusion in
turn can lead to iron overload which may result in hypog-
onadism, diabetes mellitus, hypothyroidism, hypoparath-
yroidism and other endocrine abnormalities [4]. In recent
years, several authors reported a high incidence of endo-
crine abnormalities in children, adolescents and young
adults suffering from thalassemia major. However the
incidence of the various endocrinopathies changes among
different series of the patients due to a mixture of reasons
other than iron overloads [5].
Osteoporosis is common even in well-treated thalassemic
patients [6]. There are no data reflecting the bone mineral
density status of Iranian thalassemic patients. Trace metals
deficiencies in patients with thalassemia major have been
under debate [7,8]. Trace minerals have been shown to
influence growth and hormones at several levels, and zinc
deficiency which may be considered a causative factor for
osteoporosis and endocrinopathies [9] have not been
fully studied in our patients yet.
In our country, there are more than 20,000 thalassemic
patients. We have conducted this study to establish the
pattern of endocrine function, bone changes and nutri-
tional status in Iranian thalassemic patients.
Methods
Thalassemic patients in Tehran are all registered in 12
clinics in order to receive treatment. These clinics were
ordered in a list according to the number of registered
patients. From every two consecutive centers, one was
selected with simple random method in order to select six
thalassemia clinics. Number of patients to be selected
from each clinic was calculated with proportional to size
method based on registered cases in each of these clinics.
In each clinic, patients were selected with simple random
method by using computerized tables. Two hundred fifty
eight adolescent homozygous beta-thalassemia patients
were recruited, among whom, 220 (51.5% male) accepted
to enter the study. Table 1 shows demographic data of the
study population. The diagnosis of homozygous tha-
lassemia was based on the usual hematological criteria
(peripheral blood evaluation and hemoglobin electro-
phoresis of the patients) from early years of life. Informed
consent was obtained from the patients or their parents
(in non-competent patients). The study protocol was
approved by the ethics committee of Tehran University of
medical sciences-research deputy.
Physicians collected demographic and anthropometric
data and the history of menstruation, family history of
diabetes, initiation and duration of blood transfusion, as
well as chelation therapy. Percentiles of height and weight
were determined by growth diagram provided by
National Center for Health Statistics (NCHS). Puberty sta-
tus according to Marshall-Tanner [10] determined. Char-
acteristics of study group are shown in table 1 and 2. All
subjects were transfused every 4–5 weeks with packed red
cell since early years of life in an attempt to keep their pre-
tranfusion hemoglobin above 9.5 g/dl. Our patients were
taking 20–50 mg/kg daily desferrioxamine as iron chela-
tor. Therapeutic markers of the study population are
depicted in table 2. Splenectomy had been performed on
107 of our patients (mean age of splenectomy: 9.2 ± 4.1
yr). Blood samples were drawn from patients after they
had fasted. Serum samples were stored at -20°C until ana-
lyzed. Serum 25 (OH) D was measured by radioimmu-
noassay (iDS, UK). Serum iPTH concentrations were
measured by use of an immunoradiometric method (N-
tact, DiaSorin, USA) Zinc and copper in serum were deter-
mined by flame atomic absorption spectrophotometry.
Serum level of zinc and copper was measured using
atomic absorption spectrophotometry. Serum zinc level
less than 70 µg/dL was regarded as low [11]. Serum copper
levels were normal if above 70 and 80 µg/dL for boys and
girls respectively [12]. Serum ferritin level was measured
by standard methods (microparticle enzyme
immunoassay).
Table 1: Demographic characteristics of study population (Mean 
± SD)
Age 15.2 ± 3.1(yr)
Height 146.9 ± 12.3(cm)
Weight 39.6 ± 9.7(kg)
Height for age (HAP) 13.2 ± 17.8
Weight for age (WAP) 11.9 ± 15.1
BMI 18.3 ± 3 (kg/m2)
Table 2: Therapeutic characteristics of study population (Mean ± 
SD)
Age of start of transfusion 15.4 ± 18.8(month)
Age of start of desferrioxamine 5.1 ± 3.1(yr)
Pretranfusion hemoglobin in last year 9.6 ± 2.3(g/dl)
Ferritin 1441 ± 1111.3(µg/l)BMC Endocrine Disorders 2003, 3:4 http://www.biomedcentral.com/1472-6823/3/4
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The dietary calcium, zinc and copper intakes were esti-
mated by use of food-frequency questionnaires (FFQ). We
measured lumbar spine (L1–L4) and femoral area bone
mineral density (BMD) (g/cm 2) in 212 patients, using
dual-energy x-ray absorptiometry (LUNAR,
DPXMD#7164), which was calibrated daily. Osteopenia
is defined as T score between -1 to -2.5, and osteoporosis
below -2.5 by W.H.O (1994) criteria. This definition
relates to adult women and not to children, adolescents,
men and the very old. Thus we defined osteopenia, as Z
score between -1 to -2.5, and osteoporosis below -2.5
[13].
Hypogonadism was indicated by absence of breast devel-
opment in girls and absence of testicular enlargement in
boys (less than 4 ml) as measured by Prader's orchidom-
eter by the age of 16 [14]. Impaired puberty was defined
as more than 2 SD delay in pubertal development beyond
the mean for their sex. Irregular menstrual cycles were
characterized by an unpredictable and variable interval
between menses which always occurred more frequently
than every 3 months. Primary amenorrhea was present
when the menarche has not appeared by the age of 16 or
lack of breast development by the time when a girl was 14.
Secondary amenorrhea was defined as the absence of
menstruation for a 6 months period at any time after
menarche. Body mass index (BMI) was calculated with the
following formula; BMI= weight (kg)/ height2(m2).
Patients' evaluation for endocrine complications was per-
formed annually. Bone mineral density measurement and
determination of serum zinc and copper are not compo-
nents of routine patients' workup. Thyroid function was
assessed by T3, T4 and TSH, using commercial radioim-
munoassay (RIA) to determine these parameters.
Hypothyroidism was defined according to Evered et al
[15], or based on the history of treatment with levothyrox-
ine for previously diagnosed hypothyroidism. Hypopar-
athyroidism was diagnosed when there was low serum
calcium concentration, which was measured increased
serum phosphate, low serum parathyroid hormone (with
a reference range of 13–54 pg/ml.), or if normal, a PTH
level inappropriate for the calcium level. Patients with
diabetes mellitus based on the history of insulin therapy
have been recognized (glucose tolerance test (GTT) has
not been performed).
Data were analyzed by using Statistical Package for Social
Sciences (SPSS) software (version 10.0). Numerical data
are presented as mean ± standard deviation. P < 0.05 was
considered significant. All factors were tested for their dis-
tribution model. We considered Mann-Whitney and
Kruskal Wallis tests, where distributions were not normal,
to investigate different levels of associations. Simple linear
regression has been used to show the correlation of serum
zinc and lumbar BMD. All the statistical analysis has been
done with 95% confidence interval, when appropriate.
Results
Endocrine abnormalities
In our study population, 80.8% of boys and 72.6% of girls
had impaired puberty. Serum ferritin level in this group
was 1407 ± 971 µg/l, which was not statistically signifi-
cant in comparison with patients who went normally
through puberty. Hypogonadism was seen in 22.9% of
boys and 12.2% of girls (no significant difference) with
the mean serum ferritin level equal to 1787 ± 988 µg/l that
was significantly higher than patients without hypogo-
nadism (P = 0.036). The mean age at the time of
menarche was 15.3 ± 1.7 years. Prevalence of primary
amenorrhea was 32.8 percent (19 out of 58). Serum ferri-
tin level was significantly higher in this group of patients
than those who experienced mense in time (P = 0.008).
Among 39 patients who experienced menarche, 17 and 3
had irregular mense and secondary amenorrhea, respec-
tively. None of them were overweight. Mean of serum fer-
ritin level in patients with irregular mense was 1527 ±
1073  µg/l, significantly higher than those with regular
mense (861 ± 492 µg/l) (P = 0.008). Prevalence of puber-
tal disorders is summarized in table 3. Short stature
(height below the 3rd percentile) was seen in 39.3% of our
patients. Their serum ferritin level was not different from
normal stature cases. There was no difference in preva-
lence of short stature between pre-pubertal and rest of the
study population.
There were a total of 8.7% with history of diabetes melli-
tus and all of them except one had been diagnosed after
the age of 10. The mean age at the time of diagnosis was
15 ± 3 years. No significant difference was seen between
males and females in the prevalence of diabetes mellitus
(61.1% male, 38.9% female). Serum ferritin level in tha-
lassemic patients with diabetes (1519 ± 920 µg/l) and
those without history of diabetes were not significantly
Table 3: Prevalence of pubertal disorders and menstrual 
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different. Sixteen percent of diabetic patients had a family
history of type I or type II diabetes in their siblings, par-
ents or grandparents. Four cases had been first presented
with ketoacidosis.
Primary hypothyroidism was present in 7.7% of patients
(with mean age of 16.4 ± 4.1 yr). We had five patients with
clinical hypothyroidism. Mean of ferritin was 1782 ±
1824 µg/l in this group. There was no significant differ-
ence in mean serum ferritin between hypothyroid patients
and others.
Hypoparathyroidism was found in 7.6% of patients. The
mean age of these patients was 16.9 ± 3.7 years and the
highest prevalence of hypoparathyroidism was seen in the
age of 20, with the distribution of 81.8 % in males and
18.2 % in females. The mean serum level of calcium and
phosphate was 7.6 ± 0.8 mmol/l and 4.4 ± 1.0 mmol/l
respectively. The mean serum ferritin level was 1444 ± 798
µg/l, not significantly different with other patients. Preva-
lence of endocrine complications is illustrated in figure 1.
About 10 % of patients had more than one endocrine
complication. The mean age of these patients was 18.4 ±
1.3 years. There was a significant difference (p = 0.01)
between mean serum ferritin in thalassemic patients with
endocrine complications (one or more than one compli-
cation) (1660 ± 1208 µgr/l) and thalassemic patients
without endocrinopathies (1166 ± 823 µgr/l).
Metabolic abnormalities
Prevalence of osteoporosis and osteopenia in the lumbar
(L1–L4) region were 50.7% and 39.4% respectively. These
figures showed osteoporosis and osteopenia as 10.8% and
36.9% in the femur neck. Concomitant lumbar and fem-
oral osteoporosis was observed in 7.9%, while only in
9.3% both regions were normal (above -1SD below the
mean). There was no significant difference in prevalence
of osteoporosis between boys and girls. The mean age of
osteoporotic patients was significantly higher (p < 0.05).
Mean serum zinc level was 54.6 ± 4.0 µg/dL. Serum zinc
level was lower than normal (below 70 µg/dL) in 79.6%
of patients. Mean serum level of copper was found to be
65.1 ± 3.9 µg/dL. Serum copper level was lower than nor-
mal in 68 % (less than 70 µg/dL in boys and 80 µg/dL in
girls) of our patients. Daily intake of copper and zinc was
lower than normal(less than 2–3 µg/day and 15 µg/day
for copper and zinc) in 90.1% and 91% respectively.
Serum zinc level was associated with lumbar (R2 = 0.02, p
< 0.05) but not femoral BMD. We did not find any associ-
ation between serum copper and BMD values.
Mean of daily calcium intake was 830.5 mg (ranged from
221 to 3185 mg). Low calcium intake (less than 1200 mg/
day) was observed in 84.2% of our patients, not signifi-
cantly different between genders. Mean of serum 25 (OH)
D level was 31.48 nmol/l. In 37.2% of patients serum lev-
els of 25 (OH) D below 23 nmol/l (vitamin D deficiency
on the basis of the reference range of manufacturer) was
observed.
Discussion
Impaired puberty, which occurred in approximately 77 %
of our patients, was the most common endocrine abnor-
mality. The prevalence of other endocrinopathies was
much lower: 17.5 % hypogonadism, 8.7% diabetes melli-
tus, 7.7% primary hypothyroidism, and 7.6% hypopar-
athyroidism. Three out of 39 postmenarchal patients had
secondary amenorrhea. Impaired puberty seems to be
more prevalent in our study compared to study of Italian
working group [14]. Hypogonadism in our study was con-
siderably lower than other studies. In a longitudinal
study, prevalence of hypogonadism has been reported to
be as much as 75% in girls and 62% in boys [16]. In our
study diabetes was present in 8.7% of the patients. This is
considerably higher than the 4.9% of patients developing
IDDM in a recent study by the Italian Working Group
[14]. It is unclear whether diabetes in β -thalassemia major
is related to genetic factors [14,16]. It seems that our dia-
betic patients were of younger ages at the time of diagno-
sis in comparison with other studies [14,17].
Hypothyroidism was a complication in 7.7% of our
patients. Thyroid dysfunction has been reported in 13–
60% of patients with thalassemia, but its severity is varia-
ble in different series. Some studies reported a high prev-
alence of primary hypothyroidism, reaching up to 17–
18% [18,19], While others reported low prevalence of 0–
9% [20,21]. It is important to note that even in the studies
in which the prevalence of overt hypothyroidism as a
complication of thalassemia major is relatively low,
milder forms of thyroid dysfunction are much more com-
mon [18,20,22], though again there are wide variations in
different reports. These discrepancies can not be attrib-
uted to differences in patients' ages, but rather to differ-
ence treatment protocols, including differing transfusion
rates and chelation therapies [21]. The prevalence of
hypoparathyroidism observed in our study (7.6%) is
higher than the 3.6–7% reported by other workers
[5,14,23]. The male/female ratio was 4/1. This ratio is
higher than other reports [14,24].
Short stature seemed to be more prevalent among our
patients compared to other studies [25]. Our growth
assessments did not show any difference of short stature
prevalence between prepubertal and pubertal patients, in
contrast to the results of Pignatti et al who claimed growth
abnormalities to be more prevalent in pubertal patients
[26].BMC Endocrine Disorders 2003, 3:4 http://www.biomedcentral.com/1472-6823/3/4
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High prevalence of endocrine abnormalities was reported
by several authors [14,23,27]. They demonstrated that
these abnormalities were related to iron overload. The his-
tological studies of different endocrine glands supported
this hypothesis [28,29]. We found significant difference in
mean serum ferritin level between thalassemic patients
with primary amenorrhea, irregular mense, hypogonad-
ism and those without endocrinopathies. These findings
yield the importance of iron overload in development of
endocrine disorders. In contrast, there are some other
reports which have suggested no relation between the
level of ferritin and some other endocrinopathies [30,31].
It has been suggested that the prognosis for survival is
excellent for thalassemic patients with serum ferritin con-
centration below 2500 µg/l [32]. We found a considerable
sum of endocrinopathies in our population. Taking into
account that their ferritin levels are not of high amounts,
it is possible, therefore, that there are other factors respon-
sible for organ damage. Among these factors; liver damage
due to viral infections, increased activity of the iron
dependent protocollagen proline hydroxylase enzyme,
chronic anemia and individual susceptibility to damage
from iron overload have been previously pointed out[14].
High prevalence of osteoporosis and osteopenia in our
thalassemic patients is in gross agreement with those
reported in the earlier literature, although the diversity of
the employed techniques weakens some of the compari-
sons. Similar results from other studies have also been
reported [33,34]. Jensen et al studied 82 patients who
were well transfused and who received regular desferriox-
amine. In that study, the overall prevalence of patients
with "severely low" bone mass was 51% and those with
"low" bone mass 45% [35]. We did not find any signifi-
cant difference between men and women, this finding was
in agreement with the some previous reports [36,37] but
was in contrast to the findings of Jensen et al who reported
that the bone lesions in thalassemic are more frequent
and more prominent in males [35]
Zinc deficiency is considered as one of the main factors
contributing to growth and puberty disorders in tha-
lassemic patients [38]. Our findings show serum zinc defi-
ciency in around 80% and serum copper deficiency in
about 68% of thalassemic patients studied. The zinc status
of thalassemic patients was previously reported by Arca-
soy et al and they showed that there was marked zinc defi-
ciency in the presence of hyperzincuria [39]. Kwan and
colleagues [16] reported that only 3 of their 68 tha-
lassemic patients had zinc deficiency in their study popu-
lation. Deficiencies of zinc and copper in patients with
thalassemia major have been under debate. It seems that
deficiency of serum zinc and copper in our patients could
be attributed to high prevalence of deficiency of these two
trace elements in Iranian general population [40]. Low
levels of vitamin D were previously reported in tha-
lassemic patients [41,42]; however its prevalence among
our thalassemic patients was more than most of other
reports. It may be due to high prevalence of vitamin D
deficiency in general population.
Conclusion
High prevalence of endocrine and metabolic complica-
tions among our thalassemics signifies the importance of
therapeutic interventions. The differences of these abnor-
malities in different series of patients may be due to vari-
ations in treatment protocols or different susceptibilities
and demand more detailed studies.
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